|
Author
| |
Dose* median follow-up
|
3yLC
|
3yOS
|
|---|
|
(reference)
|
n
|
(Gy)
|
(mo)
|
(%)
|
(%)
|
|---|
|
Onishi (2)
|
257
|
30-84(i)
|
38
|
NA
|
57
|
|
Timmerman (8)
|
55
|
54(p)
|
34
|
98
|
56
|
|
Nagata (10)
|
42
|
48(i)
|
30
|
NA
|
83 (T1 only)
|
|
Onimaru (21)
|
41
|
40-48(i)
|
27
|
57
|
47
|
|
Uematsu (30)
|
50
|
40-60(i)
|
60
|
NA
|
66
|
|
Koto (31)
|
31
|
45-60(i)
|
32
|
78
|
72
|
|
Nyman (32)
|
45
|
45(p)
|
43
|
80
|
55
|
|
Takeda (33)
|
38
|
50(p)
|
31
|
93 (T1 only)
|
90 (T1 only)
|
|
Taremi (34)
|
108
|
48-60(p)
|
19
|
89 (4y)
|
30 (4y)
|
|
Current study
|
109
|
48(i) or 40(p)
|
25
|
81
|
68
|
- *Dose was prescribed at the isocenter (i) or periphery (p) of the tumor.
